NEW YORK, NY--(Marketwire - February 23, 2009) - Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Fresno Heart & Surgical Hospital of Fresno, California.

Fresno Heart & Surgical Hospital is a full service acute care hospital devoted to cardiovascular and surgical care with 57 beds, including a 9 bed intensive care unit. In addition to cardiac, vascular, bariatric and general surgery in state-of-the-art surgical suites, Fresno Heart & Surgical Hospital also provides specialized cardiac catheterization and vascular interventional rooms, a cardiac evaluation center, and a complete imaging center and clinical laboratory for comprehensive diagnostic services for both inpatient and outpatient services.

The hospital has made a major commitment to develop the largest dedicated Congestive Heart Failure management program in Central California. A specially trained team of nurses and technicians work closely with physicians to manage patients with chronic heart failure on an outpatient basis to avoid recurrent hospital admissions. The ability to measure blood volume will find great utility within this specialized program.

Daxor's Blood Volume Analyzer BVA-100 will be located within Fresno Heat & Surgical Hospital's Nuclear Medicine Department. Dr. Kevin Boran, a cardiologist from the Fresno Heart & Surgical Hospital's Congestive Heart Failure Improvement Program, noted that, "A measured blood volume will provide a state-of-the-art diagnostic tool to diagnose and then treat fluid and blood requirements of our patients. We intend to utilize this diagnostic tool to contribute to improved outcomes and a reduction in the cost of care as it relates to our patients' fluid needs."

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website

Contact Information: Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 Diane Meegan Investor Relations 212-330-8512